Confirmed Conference Invited Speakers

List does not include those who are speaking only during a preconference course.
 

Owen Arthurs (UK)
Postmortem imaging: Decline of the histopathologist?

Arthur Beaudet (USA)
Will fetal cells have a place in prenatal diagnosis?

Michael Belfort (USA)
Debate:  In utero therapy for spina bifida is ready for endoscopic repair (for)

Diana Bianchi (USA)
NIPT using cfDNA beyond aneuploidy: What should we be doing?

Rabih Chaoui (Germany)
First trimester ultrasound for non-aneuploid genetic syndromes

Martina Cornel (Netherlands)
Preconception and carrier screening: The big picture

Jan Deprest (Belgium)
Debate:  In utero therapy for spina bifida is ready for endoscopic repair (against)

Wybo Dondorp (Netherlands)
Ethical principles of fetal therapy

Mark Evans (USA)
Debate:  Industry drives innovation in research and clinical application of genetic prenatal diagnosis and screening (moderator)

Jane Fisher (UK)
The good the bad and the ugly – stakeholder perceptions of NIPT for aneuploidy

Francesca Romana Grati (Italy)
Mosaicism and its implications for prenatal diagnosis

Kurt Hecher (Germany)
Debate:  In utero therapy for spina bifida is ready for endoscopic repair (moderator)

Matt Hurles (UK)
Challenges in interpretation and application of whole exome sequencing for prenatal diagnosis: Does the postnatal experience help us?

Jon Hyett (Australia)
Debate:  For those women screened by NIPT using cell free DNA maternal serum biomarkers are obsolete (against)

Karl Oliver Kagan (Germany)
Screening for aneuploidy other than DS using combined testing and fetal anomaly scanning in the first trimester: Is there a place for NIPT?

Gregor Kasprian (Austria)
Fetal MRI for detailed evaluation of cerebral structure and function

Sylvie Langlois (Canada)
Debate:  For those women screened by NIPT using cell free DNA maternal serum biomarkers are obsolete (moderator)

Enrico Lopriore (Netherlands)
Longterm outcome after fetal therapy

Thomas Musci (USA)
Debate:  Industry drives innovation in research and clinical application of genetic prenatal diagnosis and screening (for)

Claudio Mussolino (Germany)
Closing Plenary: Genome editing

Michael Parker (UK)
Ethical aspects in the new era of genomic medicine with more comprehensive testing and easier access to prenatal testing

Greg Ryan (Canada)
Fetal therapy: The state of the art

Laura Rodrigues (UK)
Closing Plenary: Zika: Epidemiology, natural history and pregnancy outcomes

Ignatia Van den Veyver (USA)
How should we approach prenatal counselling to account for VUS and secondary findings?

Tim Van Mieghem (Belgium)
Maternal complications of fetal therapy

Stefan Verlohren (Germany)
Clinical implementation of the sFLIT:PLGF ratio and other maternal serum biomarkers for the prediction of adverse pregnancy outcomes

Joris Vermeesch (Belgium)
Debate:  Industry drives innovation in research and clinical application of genetic prenatal diagnosis and screening (against)

Katerina Vesela (Czech Republic)
Implementing PGD and PGS in clinical practice

Ronald Wapner (USA)
Array CGH as first line testing for ultrasound anomalies

Yuval Yaron (Israel)
Debate:  For those women screened by NIPT using cell free DNA maternal serum biomarkers are obsolete (for)